These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 33262065)

  • 1. New viral vectors for infectious diseases and cancer.
    Sasso E; D'Alise AM; Zambrano N; Scarselli E; Folgori A; Nicosia A
    Semin Immunol; 2020 Aug; 50():101430. PubMed ID: 33262065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel viral vectors in infectious diseases.
    Humphreys IR; Sebastian S
    Immunology; 2018 Jan; 153(1):1-9. PubMed ID: 28869761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
    Sutter G; Staib C
    Curr Drug Targets Infect Disord; 2003 Sep; 3(3):263-71. PubMed ID: 14529359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
    Volz A; Sutter G
    Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of Modified Vaccinia virus Ankara vaccines.
    Gilbert SC
    Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.
    Tober R; Banki Z; Egerer L; Muik A; Behmüller S; Kreppel F; Greczmiel U; Oxenius A; von Laer D; Kimpel J
    J Virol; 2014 May; 88(9):4897-907. PubMed ID: 24554655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases.
    Perdiguero B; Pérez P; Marcos-Villar L; Albericio G; Astorgano D; Álvarez E; Sin L; Gómez CE; García-Arriaza J; Esteban M
    J Mol Biol; 2023 Aug; 435(15):168173. PubMed ID: 37301278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development.
    Lorenzo MM; Nogales A; Chiem K; Blasco R; Martínez-Sobrido L
    Microbiol Spectr; 2022 Jun; 10(3):e0027222. PubMed ID: 35583360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
    Ramsauer K; Tangy F
    J Infect Dis; 2016 Dec; 214(suppl 5):S500-S505. PubMed ID: 27920181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral vectors for malaria vaccine development.
    Li S; Locke E; Bruder J; Clarke D; Doolan DL; Havenga MJ; Hill AV; Liljestrom P; Monath TP; Naim HY; Ockenhouse C; Tang DC; Van Kampen KR; Viret JF; Zavala F; Dubovsky F
    Vaccine; 2007 Mar; 25(14):2567-74. PubMed ID: 16914237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
    J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vector-based genetically modified vaccines: Exploiting Jenner's legacy.
    Ramezanpour B; Haan I; Osterhaus A; Claassen E
    Vaccine; 2016 Dec; 34(50):6436-6448. PubMed ID: 28029542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.
    Gómez CE; Nájera JL; Krupa M; Esteban M
    Curr Gene Ther; 2008 Apr; 8(2):97-120. PubMed ID: 18393831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant MVA vaccines: dispelling the myths.
    Cottingham MG; Carroll MW
    Vaccine; 2013 Sep; 31(39):4247-51. PubMed ID: 23523407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
    Taylor J; Paoletti E
    Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies.
    Volz A; Sutter G
    Vaccine; 2013 Sep; 31(39):4235-40. PubMed ID: 23523402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
    Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
    J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccinia-based vaccines to biothreat and emerging viruses.
    Nagata LP; Irwin CR; Hu WG; Evans DH
    Biotechnol Genet Eng Rev; 2018 Apr; 34(1):107-121. PubMed ID: 29779454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.
    Naito T; Kaneko Y; Kozbor D
    J Gen Virol; 2007 Jan; 88(Pt 1):61-70. PubMed ID: 17170437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.